inōtiv Corporate Presentation June 2023

Investment Highlights 18 | Experienced team is leading efforts for integration and synergies, efforts to be realized in the near term, with measurable improvements in profitability expected Collaborative scientific engagement with clients drives future base of new revenues Full service CRO from Discovery to FDA approval Worldwide knowledge of NHP services and opportunities. Ability to audit, transport, quarantine, board, and breed NHPs, should provide reliable supply for safety assessment studies for DSA clients DSA business has demonstrated the ability to grow and gain market share We think the current environment requires agility and we believe our size, team, and recent investments, site consolidations and integration activities provide opportunity for improved margins and cash flow over next few years CORPORATE PRESENTATION inōtiv analyze, answer. advance.

View entire presentation